Recombinant Hyaluronidase (Under development)

Product Description

Antibodies are regards as anticancer "magic bullet". Monoclonal Antibody (MAb therapeutics) Market  will grow USD300 billion in 2025. For these therapeutics, a lot of companies are under development of SC formulation with recombinant Hyaluronidase (using human rHuPH20), and BMI Korea's recombinant hyaluronidase can be alternative for existing products. 

BMI Korea

  • KR
  • 2015
    On CPhI since
  • 3
    Certificates
  • 100 - 249
    Employees
Manufacturer/Innovator

BMI Korea

  • KR
  • 2015
    On CPhI since
  • 3
    Certificates
  • 100 - 249
    Employees
Manufacturer/Innovator

More Products from BMI Korea

Recommended products